Brightening agent
The brightening agent with glycosyl naringin and L-ascorbic acid glucoside effectively addresses the limitations of conventional pigmentation inhibitors by suppressing tyrosinase activity in both keratinocytes and melanocytes, achieving improved skin tone and transparency.
Patent Information
- Application Number
- JP2025077640
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-07
- Publication Date
- 2026-11-19
AI Technical Summary
Conventional active ingredients for preventing pigmentation such as skin spots and freckles, like kojic acid and ascorbic acid, are insufficient in inhibiting melanin production due to multiple mechanisms beyond tyrosinase activity, leading to inadequate brightening effects.
A brightening agent containing glycosyl naringin and L-ascorbic acid glucoside is used to suppress tyrosinase activity in both keratinocytes and melanocytes, thereby inhibiting melanin production effectively.
The combination of glycosyl naringin and L-ascorbic acid glucoside significantly suppresses pigmentation, enhances skin transparency, and improves skin tone by reducing tyrosinase activity in both cell types.
Smart Images

Figure 2026181880000001_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present invention relates to a brightening agent comprising glycosyl naringin and L-ascorbic acid glucoside as active ingredients.
BACKGROUND ART
[0002] Conventionally, as active ingredients for preventing pigmentation such as skin spots and freckles caused by factors including ultraviolet rays, kojic acid, arbutin, ellagic acid, ascorbic acid or derivatives thereof, for example, are known. The mechanism of action of these active ingredients is to suppress the production of melanin generated in melanocytes (pigment cells). It is known that in melanocytes, melanin is produced from the amino acid tyrosine by the enzyme tyrosinase, and the aforementioned kojic acid and the like exert the function as active ingredients for preventing pigmentation such as spots and freckles by inhibiting the activity of this tyrosinase (Patent Documents 1 to 5). However, there are multiple mechanisms of action by which pigmentation such as spots and freckles occurs in the skin, and there has been a problem that sufficient effect of inhibiting pigmentation cannot be obtained only by suppressing the activity of tyrosinase in melanocytes.
[0003]
PATENT DOCUMENT 1
PATENT DOCUMENT 2
PATENT DOCUMENT 3
PATENT DOCUMENT 4
PATENT DOCUMENT 5
DISCLOSURE OF THE INVENTION
PROBLEMS TO BE SOLVED BY THE INVENTION
[0004] As a result of diligently studying the problems of the conventional technology described above, the present inventors have found that by using α-glucosyl glycoside of naringin, a type of vitamin P (glucosylnaringin), and L-ascorbic acid glucoside, an ascorbic acid derivative, as active ingredients, it is possible to more effectively prevent pigmentation such as blemishes and freckles, as well as browning and dullness, improve skin tone, and enhance transparency, thereby achieving a brightening effect, and thus completing the present invention. [Means for solving the problem]
[0005] The present invention relates to a brightening agent containing glycosylnaringin and L-ascorbic acid glucoside as active ingredients. The present invention relates to a topical skin preparation containing a brightening agent with glycosylnaringin and L-ascorbic acid glucoside as active ingredients. [Effects of the Invention]
[0006] According to the present invention, by using glucosylnaringin and L-ascorbic acid glucoside as active ingredients, it is possible to provide an active ingredient that more effectively prevents pigmentation such as blemishes and freckles, as well as browning and dullness, and exhibits a brightening effect that improves the transparency of the skin. [Brief explanation of the drawing]
[0007] [Figure 1] Figure 1 shows the brightening effect of the present invention. [Modes for carrying out the invention]
[0008] Preferred embodiments of the present invention will be described in detail below. Glucosylnaringin, one of the active ingredients of the present invention, is an α-glycosyl glycoside of naringin, a type of vitamin P (see, for example, Japanese Patent Publication No. 04-013691). An α-glycosyl glycoside means that one or more glucose molecules are linked by an α-bond, and the bonding site may be either the aglycone portion or the sugar portion linked to the aglycone. Specifically, examples include α-monoglucosylnaringin (e.g., 3″-α-monoglucosylnaringin), α-maltosylnaringin, α-maltotriosylnaringin, α-maltotetraosylnaringin, and α-maltopentaosylnaringin. In the present invention, α-monoglucosylnaringin (e.g., 3″-α-monoglucosylnaringin) is particularly preferred.
[0009] In the present invention, the amount of glucosylnaringin, which is the active ingredient, incorporated into the topical skin preparation is A concentration of 0.001% to 5% by mass relative to the total amount is preferable.
[0010] Furthermore, L-ascorbic acid glucoside (also known as L-ascorbic acid 2-glucoside, 2-O-α-D-glucopyranosyl-L-ascorbic acid), one of the active ingredients of the present invention, is obtained by glycosizing L-ascorbic acid with glucose. In the present invention, the raw materials, manufacturing methods, and purification methods are not particularly limited, as long as they are generally used in topical skin preparations such as quasi-drugs and cosmetics.
[0011] In the present invention, the amount of L-ascorbic acid glucoside, which is the active ingredient, incorporated into the topical skin preparation is preferably 0.01% to 5% by mass of the total amount of the topical skin preparation.
[0012] In the present invention, the ratio of the active ingredients glucosylnaringin and L-ascorbic acid glucoside is not particularly limited, and for example, it is in the range of 1:5 to 5:5.
[0013] Test Example 1: Evaluation Test of Brightening Effect [Testing Process 1] First, normal keratinocytes (NHEK, which are epidermal keratinocytes, and the same applies hereafter) were placed in a 24-well plate containing HumediaKG2 medium (Kurabo Industries Ltd.) in a 6x10⁶ layer. 4 Seeds were sown per hole and pre-cultured for 1 day under conditions of 37°C and 5.0% CO2. Then, glucosylnaringin (GN) was added as a sample solution at concentrations of 0.1%, 0.2%, and 0.5% of the total volume of the culture medium, respectively. The following day, the culture supernatant was replaced with HBSS(-) and irradiated with ultraviolet light (50 mJ / cm²). 2 The following procedure was performed: After UV irradiation, the supernatant was replaced with Humedia KB2 medium (Kurabo Industries Ltd.) and the culture was continued. Next, the culture supernatant (UV-irradiated supernatant) was collected after 1 day of culture. For comparison, two experimental groups were established: one in which normal keratinocytes NHEK were cultured without UV irradiation and without the addition of glucosylnaringin (GN) [control UV-B(-)], and another in which normal keratinocytes NHEK were cultured with UV irradiation but without the addition of glucosylnaringin (GN) [control UV-B(+)]. The supernatants obtained from these groups were also collected.
[0014] [Testing Process 2] Normal melanocytes (NHEM) were placed in 5 × 10⁶ wells of a 96-well microplate containing DermaLife medium (Kurabo Industries Ltd.). 3 Seeds were sown per hole and pre-cultured for 1 day under conditions of 37°C and 5.0% CO2. Then, the culture supernatant of normal keratinocyte NHEK obtained in test step 1 was added to the culture medium. Here, three test groups were established: one to be added with the culture supernatant obtained in the glucosylnaringin (GN) supplementation group, one to be added with the culture supernatant obtained in the control UV-B(-), and one to be added with the culture supernatant obtained in the control UV-B(+). Furthermore, in the group added with the culture supernatant obtained in the glucosyl naringin (GN) addition group, during the culture of normal melanocyte NHEM, a test group in which L-ascorbic acid glucoside (AG) was added as a sample solution to a final concentration of 0.5% relative to the total volume of the medium, and a test group in which L-ascorbic acid glucoside (AG) was not added were set. In addition, in the group added with the culture supernatant obtained in the control UV-B(+), a test group in which L-ascorbic acid glucoside (AG) was added to a final concentration of 0.5% relative to the total volume of the medium, a test group in which L-ascorbic acid glucoside (AG) was not added and PBS(-) was added, and a test group in which kojic acid (KA) as a positive control was added to a concentration of 2 mM were set. As the test group added with the culture supernatant obtained in the control UV-B(-), PBS(-) was added without adding L-ascorbic acid glucoside (AG). The above test groups are shown in Table 1.
[0015] [Table 1] JPEG2026181880000002.jpg84122
[0016] [Test Step 3] In all test groups obtained through the above Test Step 1 and Test Step 2, after normal melanocyte NHEM was cultured for 3 days, the culture supernatant was discarded, and the cells were washed once with PBS(-), then a surfactant (Triton X-100) and 5 mM L-dopa solution were added to carry out the reaction at 37°C. Thereafter, the dopa value was measured at a wavelength of 492 nm using a microplate reader (Multiskan FC, manufactured by ThermoFisher SCIENT). For the values of the test results, the relative values of the dopa values in the control UV-B(-) test group (A) and each sample solution addition group (C to J) were calculated with the dopa value in the control UV-B(+) test group (B) taken as 100, and each value was defined as the tyrosinase activity rate (%).
[0017] The results of Test Example 1 are shown in Figure 1. First, as shown in Figure 1, it was confirmed that when the culture supernatant of keratinocytes irradiated with UV-B ultraviolet rays was added to melanocytes, the tyrosinase activity in the melanocytes was significantly enhanced (A and B in Figure 1). On the other hand, it was confirmed that even when the culture supernatant of keratinocytes cultured with added glucosyl naringin was added to melanocytes, the tyrosinase activity was suppressed compared with the control (A) (C to E in Figure 1). This result suggests that upon ultraviolet irradiation, keratinocytes secrete a factor that enhances tyrosinase activity in melanocytes, and that glucosyl naringin (GN) suppresses the secretion of the tyrosinase activity-enhancing factor from keratinocytes. Furthermore, it was also confirmed that by adding L-ascorbic acid glucoside (AG) during the culture of melanocytes, tyrosinase activity is more significantly suppressed (G to I in Figure 1).
[0018] As described above, according to the present invention containing glucosyl naringin and L-ascorbic acid glucoside as active ingredients, the secretion of the tyrosinase activity factor from keratinocytes due to ultraviolet irradiation is suppressed, and L-ascorbic acid glucoside suppresses tyrosinase activity in melanocytes, whereby it can act on two types of cells, keratinocytes and melanocytes, to suppress tyrosinase activity. As a result, it can be expected to more significantly exert a brightening effect that suppresses pigmentation such as skin spots and freckles as well as dull yellowish skin tone, improves skin color tone, and enhances transparency.
[0019] Examples of the external skin preparation (cosmetics, quasi-drugs, external pharmaceutical products) incorporating the brightening agent containing glucosyl naringin and L-ascorbic acid glucoside as active ingredients according to the present invention include emulsions, creams, lotions, essences, packs, lipsticks, foundations, sheet masks, sunscreens, liquid foundations, makeup pressed powders, blushes, face powders, facial cleansers, body shampoos, hair shampoos, cleansing cosmetics such as soaps, and further bath agents, but are of course not limited to these.
[0020] Furthermore, when incorporating it into topical skin preparations (cosmetics, quasi-drugs, and topical pharmaceuticals, etc.), ingredients used in topical skin preparations, such as oily components, surfactants (synthetic and natural), humectants, thickeners, emulsifiers or emulsifying aids, preservatives and bactericides, powder components, UV absorbers, antioxidants, pigments, fragrances, etc., can be added as needed.
[0021] Oily components include, for example, plant-derived oils and fats such as olive oil, jojoba oil, castor oil, soybean oil, rice bran oil, rice germ oil, coconut oil, palm oil, cocoa oil, meadowfoam oil, shea butter, tea tree oil, avocado oil, macadamia nut oil, bergamot oil, lavender oil, rose oil, chamomile oil, etc.; vitamin A oil; animal-derived oils and fats such as mink oil and turtle oil; waxes such as beeswax, carnauba wax, rice wax, and lanolin; liquid paraffin, petrolatum, and paraffin wax. Examples include hydrocarbons such as squalane; fatty acids such as myristic acid, palmitic acid, stearic acid, oleic acid, isostearic acid, and cis-11-eicosenoic acid; higher alcohols such as lauryl alcohol, cetanol, pantothenyl alcohol, and stearyl alcohol; synthetic esters and synthetic triglycerides such as isopropyl myristate, isopropyl palmitate, butyl oleate, 2-ethylhexylglyceride, and higher fatty acid octyldodecyl (octyldodecyl stearate, etc.).
[0022] Examples of surfactants include nonionic surfactants such as polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyoxyethylene hydrogenated castor oil, and polyoxyethylene sorbitol fatty acid esters; fatty acid salts, alkyl sulfates, alkylbenzene sulfonates, polyoxyethylene alkyl ether sulfates, polyoxyethylene fatty amine sulfates, polyoxyethylene alkylphenyl ether sulfates, polyoxyethylene alkyl ether phosphates, α-sulfonated fatty acid alkyl ester salts, and polyoxyethylene Anionic surfactants such as ethylene alkylphenyl ether phosphates; cationic surfactants such as quaternary ammonium salts, primary to tertiary fatty amine salts, trialkylbenzylammonium salts, alkylpyridinium salts, 2-alkyl-1-alkyl-1-hydroxyethylimidazolinium salts, N,N-dialkylmorphonium salts, polyethylene polyamine fatty acid amide salts; and amphoteric surfactants such as N,N-dimethyl-N-alkyl-N-carboxymethylammonium betaine, N,N,N-trialkyl-N-alkyleneammonium carboxybetaine, and N-acylamidopropyl-N′,N′-dimethyl-N′-β-hydroxypropylammonium sulfobetaine can be used.
[0023] Emulsifiers and / or emulsifying aids may also include stevia derivatives such as enzyme-treated stevia, saponins or their derivatives, casein or its salts (such as sodium), sugar-protein complexes, sucrose or its esters, lactose, water-soluble polysaccharides derived from soybeans, soybean-derived protein-polysaccharide complexes, lanolin or its derivatives, cholesterol, stevia derivatives (such as enzyme-treated stevia), silicates (such as aluminum and magnesium), carbonates (such as calcium and sodium), saponins and their derivatives, etc.
[0024] Examples of humectants include glycerin, propylene glycol, dipropylene glycol, 1,3-butylene glycol, polyethylene glycol, sorbitol, xylitol, sodium pyrrolidone carboxylate, and sugars such as trehalose and raffinose, mucopolysaccharides (e.g., hyaluronic acid and its derivatives, hyaluronic acid ferment filtrate, chondroitin and its derivatives, heparin and its derivatives), NMF-related substances, lactic acid, urea, higher fatty acid octyldodecyl, estradiol, various amino acids and their derivatives.
[0025] Examples of thickening agents include components derived from brown algae, green algae, or red algae such as alginic acid, agar, carrageenan, and fucoidan; polysaccharides such as pectin and aloe polysaccharide; gums such as tragacanth gum, locust bean gum, xanthan gum, and guar gum; cellulose derivatives such as carboxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose; synthetic polymers such as carboxyvinyl polymer, alkyl-modified carboxyvinyl polymer, polyvinyl alcohol, polyvinylpyrrolidone, and acrylic acid / methacrylic acid copolymer; hyaluronic acid and its derivatives; polyglutamic acid and its derivatives, polyacrylic acid, etc.
[0026] Anti-inflammatory agents include allantoin, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, β-glycyrrhetinic acid, stearyl glycyrrhetinate, ε-aminocaproic acid, d-camphor, dl-camphor, zinc oxide, panthenol, pyridoxine hydrochloride, and riboflavin or its derivatives.
[0027] Examples of preservatives and disinfectants include urea; benzoic acid or its salts, parahydroxybenzoic acid esters such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate; phenoxyethanol, dichlorophene, hexachlorophene, chlorhexidine hydrochloride, benzalkonium chloride, salicylic acid, sodium salicylate, zinc pyrithione, benzalkonium chloride, ethanol, undecylenic acid, phenols, and aluminum bromide. These include chloroisoquinolinium, resorcinol, jamal (imidazodinylurea), isopropylmethylphenol, triclosan, trichlorocarbanide, trichlorohydroxydiphenol ether, hinokitiol, 1,2-pentanediol, propanediol, concentrated benzalkonium chloride solution 50, essential oils such as peppermint oil and eucalyptus oil, tree bark distillates, radish ferment filtrate, ethanol derived from plants such as sugarcane and corn, or 1,3-butylene glycol.
[0028] Examples of cell activators include pantothenyl alcohol, menthol, dl-menthol, and γ-oryzanol.
[0029] Examples of anti-acne agents include sulfur, salicylic acid or its salts, photosensitizer 201, and pyridoxine dicaprylate.
[0030] Examples of powder components include sericite, titanium dioxide, talc, kaolin, bentonite, zinc oxide, magnesium carbonate, magnesium oxide, zirconium oxide, barium sulfate, anhydrous silicic acid, mica, nylon powder, polyethylene powder, silk powder, cellulose-based powders, grain powders (rice, wheat, corn, millet, etc.), and legume powders (soybeans, adzuki beans, etc.).
[0031] Examples of UV absorbers include ethyl para-aminobenzoate, ethylhexyl para-dimethylaminobenzoate, amyl salicylate and its derivatives, 2-ethylhexyl para-methoxycinnamate, octyl cinnamate, oxybenzone, 2,4-dihydroxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonate, 4-tert-butyl-4-methoxybenzoylmethane, 2-(2-hydroxy-5-methylphenyl)benzotriazole, urocanic acid, ethyl urocanate, and aloe extract.
[0032] Examples of antioxidants include butylhydroxyanisole, butylhydroxytoluene, propyl gallate, and carotenoids such as astaxanthin.
[0033] Example prescription 1. Lotion [Ingredients] Part Jojoba oil 1.0 Glycerin 5.0 Glucosylnaringin 0.5 L-ascorbic acid glucoside 0.5 Dipotassium glycyrrhizinate 0.1 1,3-Butylene glycol 1.0 Water-soluble collagen 0.01 Propanediol 3.0 Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
[0034] Prescription example 2. Lotion [Ingredients] Part Squalane 1.0 Glycerin 5.0 Arbutin 3.0 Glucosylnaringin 1.0 L-ascorbic acid glucoside 2.0 1,3-Butylene glycol 1.0 Hydrolyzed collagen 0.1 Pentanediol 3.0 Sodium citrate (appropriate amount) Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
[0035] Prescription example 3. Lotion [Ingredients] Part Hydrogenated castor oil 1.0 Glycerin 5.0 Glucosylnaringin 1.0 L-ascorbic acid glucoside 2.0 Tocopherol acetate 0.3 Water-soluble collagen 0.01 1,3-Butylene glycol 1.0 Pentanediol 3.0 Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
[0036] Prescription example 4. Emulsion [Ingredients] Part Squalane 5.0 Jojoba oil 1.0 Orange peel oil 1.0 Polyoxyethylene (20) sorbitan monostearate 1.0 Lipophilic glyceryl stearate 1.0 Hydrogenated soy lecithin 1.5 Glucosylnaringin 1.0 L-ascorbic acid glucoside 2.0 Dipotassium glycyrrhizinate 0.05 Glycerin 3.0 Carboxymethylcellulose 0.3 Xanthan gum 0.2 Sodium hyaluronate 0.01 1,3-Butylene glycol 0.1 Phenoxyethanol 0.5 Pentylene glycol 0.5 Diglycerin 0.3 Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
[0037] Prescription example 5. Emulsion [Ingredients] Part Squalane 5.0 Castor oil 1.0 Lipophilic glyceryl stearate 1.0 Hydrogenated soy lecithin 1.5 Glucosylnaringin 1.0 L-ascorbic acid glucoside 2.0 Glycerin 3.0 Carboxymethylcellulose 0.3 Sodium hyaluronate 0.01 Hydrolyzed hyaluronic acid 0.01 1,3-Butylene glycol 0.1 Phenoxyethanol 0.5 Pentylene glycol 0.5 Diglycerin 0.3 Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
[0038] Prescription example 6. Cream [Ingredients] Part Olive oil 5.0 Jojoba oil 5.0 Squalane 5.0 Palmitic acid 2.5 Glucosylnaringin 1.0 L-ascorbic acid glucoside 2.0 Hydrogenated lecithin 2.0 Carboxyvinyl polymer 0.3 Sodium alginate 0.2 Water-soluble collagen 0.1 1,3-Butylene glycol 0.1 Phenoxyethanol 0.5 Pentylene glycol 0.5 Diglycerin 0.3 Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
[0039] Prescription example 7. Facial cleanser [Ingredients] Part Glyceryl stearate 2.5 Squalane 3.0 Glycerin 3.0 Polyglyceryl-10 laurate 3.0 Glucosylnaringin 1.0 L-ascorbic acid glucoside 2.0 Water-soluble collagen 0.01 Sodium hyaluronate 0.01 Potassium hydroxide (appropriate amount) Purified water, in an amount that makes the total volume 100 parts
Claims
1. A brightening agent containing glucosylnaringin and L-ascorbic acid glucoside as active ingredients.
2. A topical skin preparation comprising the agent described in claim 1.
